+

PE20181270A1 - Anticuerpo que neutraliza el virus respiratorio sincitial humano - Google Patents

Anticuerpo que neutraliza el virus respiratorio sincitial humano

Info

Publication number
PE20181270A1
PE20181270A1 PE2018000607A PE2018000607A PE20181270A1 PE 20181270 A1 PE20181270 A1 PE 20181270A1 PE 2018000607 A PE2018000607 A PE 2018000607A PE 2018000607 A PE2018000607 A PE 2018000607A PE 20181270 A1 PE20181270 A1 PE 20181270A1
Authority
PE
Peru
Prior art keywords
amino acid
acid sequence
variable region
sequence seq
antibody
Prior art date
Application number
PE2018000607A
Other languages
English (en)
Inventor
Kalpit A Vora
Kara S Cox
Aimin Tang
Zhifeng Chen
Daniel Distefano
Lan Zhang
Hua-Poo Su
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PE20181270A1 publication Critical patent/PE20181270A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Referido a un anticuerpo aislado o fragmento de union al antigeno del mismo que se une a la proteina F del virus respiratorio sincitial humano (VRS humano), en el que el anticuerpo o fragmento de union al antigeno comprende una region variable de la cadena pesada CDR 1 que comprende la secuencia de aminoacidos de SEQ ID NO:1, una region variable de la cadena pesada CDR2 que comprende la secuencia de aminoacidos SEQ ID NO:2, una region variable de la cadena pesada CDR3 que comprende la secuencia de aminoacidos SEQ ID NO:3, una region variable de la cadena ligera CDR1 que comprende la secuencia de aminoacidos SEQ ID NO:4, una region variable de la cadena ligera CR2 que comprende la secuencia de aminoacidos SEQ ID NO:5, y una region variable de la cadena ligera CDR3 que comprende la secuencia de aminoacidos SEQ ID NO:6. Tambien se refiere a acidos nucleicos aislados que codifican estos anticuerpos, un vector de expresion que comprende el acido nucleico y celulas huesped transformadas con los mismos. Ademas, se refiere a metodos de diagnostico, profilacticos y terapeuticos que emplean los estos anticuerpos, ya que tienen altos titulos neutralizantes anti-VRS, particularmente como un agente de inmunoterapia pasiva en lactantes y ancianos.
PE2018000607A 2015-10-29 2016-10-27 Anticuerpo que neutraliza el virus respiratorio sincitial humano PE20181270A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562247841P 2015-10-29 2015-10-29
US201662367359P 2016-07-27 2016-07-27

Publications (1)

Publication Number Publication Date
PE20181270A1 true PE20181270A1 (es) 2018-08-03

Family

ID=57227165

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000607A PE20181270A1 (es) 2015-10-29 2016-10-27 Anticuerpo que neutraliza el virus respiratorio sincitial humano

Country Status (27)

Country Link
US (8) US9963500B2 (es)
EP (1) EP3368562A1 (es)
JP (1) JP6880014B2 (es)
KR (1) KR102140113B1 (es)
CN (1) CN108431036B (es)
AU (3) AU2016344070B2 (es)
BR (1) BR112018008577A8 (es)
CA (1) CA3001878C (es)
CL (1) CL2018001141A1 (es)
CO (1) CO2018004321A2 (es)
GE (1) GEP20217260B (es)
HK (1) HK1254950A1 (es)
IL (1) IL258743B2 (es)
JO (2) JO3555B1 (es)
MA (1) MA43108A (es)
MX (1) MX389274B (es)
MY (1) MY192714A (es)
NI (1) NI201800052A (es)
PE (1) PE20181270A1 (es)
PH (1) PH12018500916A1 (es)
SG (2) SG10201809694PA (es)
SV (1) SV2018005678A (es)
TN (1) TN2018000134A1 (es)
TW (1) TWI743057B (es)
UA (1) UA127516C2 (es)
WO (1) WO2017075124A1 (es)
ZA (1) ZA201802369B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
WO2019075433A1 (en) * 2017-10-13 2019-04-18 Adimab, Llc ANTIBODIES AGAINST SYNCYTIAL RESPIRATORY VIRUS AND METHODS FOR THEIR GENERATION AND USE
CN111655715A (zh) 2018-01-29 2020-09-11 默沙东公司 稳定化的rsv f蛋白及其用途
CN111936513A (zh) * 2018-01-31 2020-11-13 威斯塔解剖学和生物学研究所 用于抗呼吸道合胞病毒的核酸抗体构筑体
WO2019165019A1 (en) * 2018-02-21 2019-08-29 Vanderbilt University Antibodies to human respiratory syncytial virus protein f pre-fusion conformation and methods of use therefor
EP3833677A4 (en) * 2018-08-08 2022-04-27 Trellis Bioscience, Inc. IMPROVED PASSIVE AND ACTIVE VACCINES AGAINST RSV
EP3867271A4 (en) * 2018-10-18 2022-08-03 Merck Sharp & Dohme Corp. FORMULATIONS OF ANTI-RSV ANTIBODIES AND METHODS OF USE
WO2020124846A1 (zh) * 2018-12-18 2020-06-25 珠海泰诺麦博生物技术有限公司 抗呼吸道合胞病毒的中和抗体及其应用
CN111606993B (zh) * 2019-02-26 2022-06-28 中国科学院上海生命科学研究院 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用
KR102467943B1 (ko) * 2020-06-25 2022-11-16 재단법인 목암생명과학연구소 항-rsv 항체 및 이를 포함하는 약학적 조성물
CN116785427B (zh) * 2020-12-18 2024-04-12 珠海泰诺麦博制药股份有限公司 呼吸道合胞病毒特异性结合分子的用途
CN115466326B (zh) * 2021-06-11 2024-06-04 中国科学院微生物研究所 一种呼吸道合胞病毒的人源单克隆抗体及其应用
WO2022268120A1 (en) * 2021-06-22 2022-12-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-rsv antibodies and uses thereof
US20250026815A1 (en) * 2021-08-25 2025-01-23 Gan & Lee Pharmaceuticals Co., Ltd. Anti-rsv antibody and application thereof
EP4446339A1 (en) * 2021-12-06 2024-10-16 Xiamen University Antibody for recognizing rsv pre-f protein and use thereof
CN119264248A (zh) 2022-07-22 2025-01-07 北京智仁美博生物科技有限公司 抗呼吸道合胞病毒中和性抗体及其用途
WO2024067151A1 (zh) * 2022-09-27 2024-04-04 深圳重链生物科技有限公司 抗呼吸道合胞病毒抗体及其相关应用
WO2024120517A1 (zh) * 2022-12-08 2024-06-13 南京诺唯赞生物科技股份有限公司 特异性结合rsv的抗体
CN117720650B (zh) * 2024-02-04 2024-07-02 北京百普赛斯生物科技股份有限公司 抗人呼吸道合胞病毒抗体及其应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1319120C (en) 1985-04-01 1993-06-15 John Henry Kenten Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
GB9207479D0 (en) 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6685942B1 (en) 1993-12-10 2004-02-03 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
ATE231002T1 (de) 1992-09-16 2003-02-15 Scripps Research Inst Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
PT853487E (pt) 1995-09-18 2000-11-30 Intracel Corp Anticorpos monoclonais neutralizantes para o virus dos sincicios respiratorios
US20020141990A1 (en) 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
JP2001510329A (ja) 1996-11-01 2001-07-31 スミスクライン・ビーチャム・コーポレイション ヒトモノクローナル抗体
US5842307A (en) 1996-11-15 1998-12-01 May; Kenzel Self-adjusting, automatic spot weed sprayer
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
EP2275541B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
AR030019A1 (es) 1999-05-18 2003-08-13 Smithkline Beecham Corp Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
US20050175986A1 (en) 2000-05-09 2005-08-11 Smit Kline Beecham Corporation Human monoclonal antibody
DE60139720D1 (de) 2000-06-28 2009-10-08 Glycofi Inc Verfahren für die Herstellung modifizierter Glykoproteine
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
WO2006014679A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
US7807165B2 (en) 2004-07-30 2010-10-05 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
TW200636064A (en) * 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
CA2585891A1 (en) 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
AU2006234847A1 (en) 2005-04-08 2006-10-19 Medimmune, Llc Antibodies against mammalian metapneumovirus
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
BRPI0817257A2 (pt) 2007-09-24 2015-06-16 Univ Vanderbilt Anticorpos moniclonais para vírus sincital respiratório e usos dos mesmos
PL3208612T3 (pl) 2008-04-09 2020-03-31 Genentech, Inc. Kompozycje i sposoby leczenia chorób o podłożu immunologicznym
DK2464664T3 (da) 2009-08-13 2016-01-18 Crucell Holland Bv Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
AU2009353693B2 (en) 2009-10-06 2016-07-21 Medimmune Ltd RSV-specific binding molecule
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
NZ718973A (en) 2010-07-09 2019-01-25 Janssen Vaccines & Prevention Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
US20140141037A1 (en) 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers
KR20150085843A (ko) 2012-11-20 2015-07-24 글락소스미스클라인 바이오로지칼즈 에스.에이. Rsv f 융합전 삼합체
US9327014B2 (en) 2012-12-04 2016-05-03 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
LT2950886T (lt) 2013-02-01 2020-07-10 Medimmune, Llc Respiracinio sincitinio viruso f baltymo epitopai
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法

Also Published As

Publication number Publication date
PH12018500916A1 (en) 2018-11-05
US20210188951A1 (en) 2021-06-24
BR112018008577A2 (pt) 2018-10-30
US11566065B2 (en) 2023-01-31
BR112018008577A8 (pt) 2023-02-07
ZA201802369B (en) 2019-01-30
MX389274B (es) 2025-03-20
MX2018005047A (es) 2018-09-06
GEP20217260B (en) 2021-05-25
KR20180069056A (ko) 2018-06-22
US11981726B2 (en) 2024-05-14
SV2018005678A (es) 2018-12-14
CO2018004321A2 (es) 2018-11-22
JP6880014B2 (ja) 2021-06-02
SG11201803524UA (en) 2018-05-30
CL2018001141A1 (es) 2018-10-12
US10323079B2 (en) 2019-06-18
AU2020200729A1 (en) 2020-02-20
US20180215808A1 (en) 2018-08-02
US20230212269A1 (en) 2023-07-06
US20170121394A1 (en) 2017-05-04
CA3001878A1 (en) 2017-05-04
US11008380B2 (en) 2021-05-18
US10072072B2 (en) 2018-09-11
HK1254950A1 (zh) 2019-08-02
TW201722991A (zh) 2017-07-01
CA3001878C (en) 2023-02-14
MA43108A (fr) 2018-09-05
IL258743B2 (en) 2023-03-01
US9963500B2 (en) 2018-05-08
IL258743B (en) 2022-11-01
TN2018000134A1 (en) 2019-10-04
JP2019503648A (ja) 2019-02-14
JOP20200091A1 (ar) 2022-10-30
SG10201809694PA (en) 2018-12-28
TWI743057B (zh) 2021-10-21
NI201800052A (es) 2018-07-24
US10358480B2 (en) 2019-07-23
EP3368562A1 (en) 2018-09-05
CN108431036A (zh) 2018-08-21
CN108431036B (zh) 2022-06-14
KR102140113B1 (ko) 2020-07-31
JO3555B1 (ar) 2020-07-05
US20240247052A1 (en) 2024-07-25
AU2016344070A1 (en) 2018-05-10
UA127516C2 (uk) 2023-09-20
AU2022202475A1 (en) 2022-05-05
US20180215810A1 (en) 2018-08-02
US20180215809A1 (en) 2018-08-02
AU2016344070B2 (en) 2019-11-07
IL258743A (en) 2018-06-28
US20200002407A1 (en) 2020-01-02
WO2017075124A1 (en) 2017-05-04
MY192714A (en) 2022-09-05

Similar Documents

Publication Publication Date Title
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20190737A1 (es) Anticuerpos anti-cd27
AR096687A1 (es) Anticuerpos anti-fcrh5
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
HRP20161740T1 (hr) Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
HRP20240719T1 (hr) Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba
PE20181336A1 (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
AR101875A1 (es) Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas
NZ631007A (en) Anti-c5 antibodies having improved pharmacokinetics
AR099855A1 (es) Anticuerpos hemaglutinina del virus antiinfluenza b y métodos de uso
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
PE20161221A1 (es) Anticuerpos de il-21
PE20161311A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载